Nusinersen

Drug Profile

Nusinersen

Alternative Names: BIIB 058; IONIS-SMNRx; ISIS-396443; ISIS-SMNRx; Spinraza

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genzyme Corporation; Isis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Spinal muscular atrophy gene therapies
  • Mechanism of Action Survival of motor neuron 2 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Spinal muscular atrophy

Most Recent Events

  • 26 Jan 2017 Launched for Spinal muscular atrophy (In adolescents, In children, In infants, In neonates, In adults) in USA (Intrathecal)
  • 13 Jan 2017 End-of-study efficacy and adverse events data from the phase III ENDEAR trial in Spinal muscular atrophy released by Biogen
  • 23 Dec 2016 Preregistration for Spinal muscular atrophy (In adolescents, In children, In infants, In adults, In neonates) in Japan, Canada, Australia (Intrathecal) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top